Physician profile
Rodney Sidransky
NPI 1417212739
$9,410.02
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.45 · 2020: $1,873 · 2021: $1,541 · 2022: $1,850 · 2023: $2,443 · 2024: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,066.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,206.68 | 2020-2024 | Caplyta |
| Lundbeck LLC | $852.74 | 2020-2024 | Rexulti |
| Abbvie INC. | $850.41 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $787.30 | 2019-2024 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $704.49 | 2020-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $680.20 | 2020-2024 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $607.08 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $589.78 | 2021-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $384.03 | 2019-2024 | Ingrezza |
| Bausch Health US, LLC | $372.42 | 2020-2024 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $362.53 | 2020-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $337.14 | 2020-2024 | Invega Sustenna, Spravato |
| Corium, LLC | $299.11 | 2022-2024 | Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $255.01 | 2021-2022 | |
| Allergan, INC. | $251.91 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $238.35 | 2020-2024 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $202.07 | 2022-2023 | Auvelity |
| Merck Sharp & Dohme LLC | $90.90 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $76.17 | 2022-2023 | Quviviq |
| Eisai INC. | $55.71 | 2020 | |
| Ironshore Pharmaceuticals INC. | $43.62 | 2020-2022 | |
| Almatica Pharma LLC | $43.34 | 2022 | |
| Alfasigma USA, INC. | $34.99 | 2020 | |
| Avanir Pharmaceuticals, INC. | $22.17 | 2022 | |
| Livanova USA, INC. | $19.42 | 2022 | |
| Tris Pharma INC | $15.80 | 2021 | |
| Adlon Therapeutics L.P. | $13.68 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Sidransky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.